search
Back to results

Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment

Primary Purpose

Diabetes, Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
repaglinide
gliclazide
Sponsored by
Novo Nordisk A/S
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Type 2 diabetes
  • Oral anti-diabetic drug (OAD) naïve (unsystematic OAD treatment 6 months prior to this trial is allowed)
  • Insulin naïve (less than 1 week of daily use of insulin therapy before trial start is allowed)
  • Lipid-lowing agent naïve
  • HbA1c: 6.5-8.5%
  • Fasting glucose: 6.1-13.0 mmol/L (110-234 mg/dl)
  • Body Mass Index (BMI): 20-35 kg/m^2
  • Be able and willing to perform self-monitored plasma glucose (SMPG)
  • Be able and willing to eat 3 main meals per day
  • Only applicable to subjects who will participate in the subgroup study: Be able and willing to perform and complete IVGTT (intravenous glucose tolerance test) at additional visits

Exclusion Criteria:

  • Known or suspected allergy to repaglinide, gliclazide, or related products (for example sulfonamide or other sulphonylureas (SUs)), or any of the excipients in the study drugs
  • Previous participation in this study
  • Participation in a study of another investigational drug within 1 month prior to study start

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

repaglinide

gliclazide

Arm Description

1 mg repaglinide twice daily (weeks 0-4), titrated (individually adjusted) to maintenance dose (weeks 4-16). Maximum dose is 4 mg three times daily

80 mg gliclazide once daily (weeks 0-4), titrated (individually adjusted) to maintenance dose (weeks 4-16). Maximum dose is 160 mg twice daily

Outcomes

Primary Outcome Measures

Change in Glycosylated Haemoglobin (HbA1c)

Secondary Outcome Measures

Change in Fasting Plasma Glucose
Change in 2-hour Postprandial Plasma Glucose (PPG) Over a Standard Meal
A standard meal contains 100g carbohydrate
Percentage of Participants Achieving the Treatment Target of HbA1c Below or Equal to 6.5%
Change in Fasting Serum Free Fatty Acid (FFA) From Baseline
Change in 2-hour Postprandial Serum Free Fatty Acid (FFA) Over a Standard Meal
Change in AUC0-180 of Serum Insulin Concentration of IVGTT (Intravenous Glucose Tolerance Test)
Change in AUC0-180 of Plasma Glucose Concentration of IVGTT
Number of All Treatment Emergent Hypoglycaemic Episodes
A hypoglycaemic episode was defined as treatment emergent if the onset of the episode was on or after the first day of trial product and no later than the last day of the trial product.
Cholesterol
The number of participants having a change in cholesterol from "normal" to "abnormal". "Abnormal" means a value of blood cholesterol is out of the normal range.
Change in Body Weight

Full Information

First Posted
November 26, 2009
Last Updated
June 25, 2014
Sponsor
Novo Nordisk A/S
search

1. Study Identification

Unique Protocol Identification Number
NCT01022762
Brief Title
Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment
Official Title
A 16-week, Multicentre, Randomised, Open-label, Parallel Group Study to Investigate the Efficacy and Safety Profiles of Repaglinide Monotherapy Compared to Gliclazide Monotherapy in Chinese Antidiabetic-naïve Subjects With Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
June 2014
Overall Recruitment Status
Completed
Study Start Date
November 2009 (undefined)
Primary Completion Date
November 2010 (Actual)
Study Completion Date
November 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novo Nordisk A/S

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This trial is conducted in Asia. The aim of this clinical trial is to investigate the blood glucose lowering effect and the safety profile of repaglinide given alone compared to gliclazide given alone in Chinese subjects with type 2 diabetes who never have been treated with oral anti-diabetic drugs (OADs). This study also investigates the augment effect of repaglinide on the phases of insulin secretion as a subgroup study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes, Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
440 (Actual)

8. Arms, Groups, and Interventions

Arm Title
repaglinide
Arm Type
Active Comparator
Arm Description
1 mg repaglinide twice daily (weeks 0-4), titrated (individually adjusted) to maintenance dose (weeks 4-16). Maximum dose is 4 mg three times daily
Arm Title
gliclazide
Arm Type
Active Comparator
Arm Description
80 mg gliclazide once daily (weeks 0-4), titrated (individually adjusted) to maintenance dose (weeks 4-16). Maximum dose is 160 mg twice daily
Intervention Type
Drug
Intervention Name(s)
repaglinide
Intervention Description
Individually adjusted dose for 16 weeks
Intervention Type
Drug
Intervention Name(s)
gliclazide
Intervention Description
Individually adjusted dose for 16 weeks
Primary Outcome Measure Information:
Title
Change in Glycosylated Haemoglobin (HbA1c)
Time Frame
Week 0, week 16
Secondary Outcome Measure Information:
Title
Change in Fasting Plasma Glucose
Time Frame
Week 0, week 16
Title
Change in 2-hour Postprandial Plasma Glucose (PPG) Over a Standard Meal
Description
A standard meal contains 100g carbohydrate
Time Frame
Week 0, week 16
Title
Percentage of Participants Achieving the Treatment Target of HbA1c Below or Equal to 6.5%
Time Frame
Week 16
Title
Change in Fasting Serum Free Fatty Acid (FFA) From Baseline
Time Frame
Week 0, week 16
Title
Change in 2-hour Postprandial Serum Free Fatty Acid (FFA) Over a Standard Meal
Time Frame
Week 0, week 16
Title
Change in AUC0-180 of Serum Insulin Concentration of IVGTT (Intravenous Glucose Tolerance Test)
Time Frame
Over the course of three hours at Week 0 and Week 16
Title
Change in AUC0-180 of Plasma Glucose Concentration of IVGTT
Time Frame
Over the course of three hours at Week 0 and Week 16
Title
Number of All Treatment Emergent Hypoglycaemic Episodes
Description
A hypoglycaemic episode was defined as treatment emergent if the onset of the episode was on or after the first day of trial product and no later than the last day of the trial product.
Time Frame
Weeks 0-16
Title
Cholesterol
Description
The number of participants having a change in cholesterol from "normal" to "abnormal". "Abnormal" means a value of blood cholesterol is out of the normal range.
Time Frame
Week 0, week 16
Title
Change in Body Weight
Time Frame
Week 0, week 16

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Type 2 diabetes Oral anti-diabetic drug (OAD) naïve (unsystematic OAD treatment 6 months prior to this trial is allowed) Insulin naïve (less than 1 week of daily use of insulin therapy before trial start is allowed) Lipid-lowing agent naïve HbA1c: 6.5-8.5% Fasting glucose: 6.1-13.0 mmol/L (110-234 mg/dl) Body Mass Index (BMI): 20-35 kg/m^2 Be able and willing to perform self-monitored plasma glucose (SMPG) Be able and willing to eat 3 main meals per day Only applicable to subjects who will participate in the subgroup study: Be able and willing to perform and complete IVGTT (intravenous glucose tolerance test) at additional visits Exclusion Criteria: Known or suspected allergy to repaglinide, gliclazide, or related products (for example sulfonamide or other sulphonylureas (SUs)), or any of the excipients in the study drugs Previous participation in this study Participation in a study of another investigational drug within 1 month prior to study start
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Global Clinical Registry (GCR, 1452)
Organizational Affiliation
Novo Nordisk A/S
Official's Role
Study Director
Facility Information:
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200025
Country
China

12. IPD Sharing Statement

Links:
URL
http://novonordisk-trials.com
Description
Clinical Trials at Novo Nordisk

Learn more about this trial

Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment

We'll reach out to this number within 24 hrs